Adma Biologics reported $88.82M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Adma Biologics USD 88.82M 13.19M Dec/2025
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Novavax USD 125.04M 76.09M Dec/2025
Omeros USD -33.16M 18.52M Jun/2024
Takeda JPY 688.84B 101.71B Mar/2026